{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T18:57:34Z","timestamp":1769885854518,"version":"3.49.0"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2023,3,20]],"date-time":"2023-03-20T00:00:00Z","timestamp":1679270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,2,26]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>To assess the usefulness and onset of nocebo effects after switching from the original etanercept (ETN) to a biosimilar (BS) in routine clinical practice at rheumatology clinics in Japan (13 sites).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A total of 165 patients (87.0% women, age\u2009=\u200957.88\u2009\u00b1\u200915.07\u2009years, and disease duration\u2009=\u200910.32\u2009\u00b1\u20097.71\u2009years), whose low disease activity was maintained with the original ETN for \u226512\u2009weeks, and who agreed to switch treatment to its BS, were included. The end-points were disease activity score 28 (DAS28)-C-reactive protein and DAS28-erythrocyte sedimentation rate.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>No significant difference was observed between the changes in DAS28-C-reactive protein and DAS28-erythrocyte sedimentation rate &amp;gt;12\u2009weeks before switching and &amp;gt;12\u2009weeks after switching (P\u2009=\u20090.132 and 0.334, respectively). The treatment continuation rate during the 52\u2009weeks after switching to BS was 97.3%. During this period, BS was discontinued in only four patients, and no nocebo effects were suspected in these four patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Switching from ETN to BS was effective even in routine clinical practice at rheumatology clinics in Japan, and no nocebo effects were observed. Sufficient explanations to patients by rheumatologists and the additional payment for drug costs between patients at hospital visits effectively improved the continuation rate without any nocebo effect.<\/jats:p><\/jats:sec>","DOI":"10.1093\/mr\/road027","type":"journal-article","created":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T23:18:18Z","timestamp":1679440698000},"page":"307-312","source":"Crossref","is-referenced-by-count":3,"title":["Investigation of treatment continuity, usefulness, and nocebo effect in switching from the original etanercept to its biosimilar in patients with rheumatoid arthritis: A JET observational study in Japanese clinical practice"],"prefix":"10.1093","volume":"34","author":[{"given":"Tsukasa","family":"Matsubara","sequence":"first","affiliation":[{"name":"Matsubara Mayflower Hospital , Hyogo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kou","family":"Katayama","sequence":"additional","affiliation":[{"name":"Katayama Orthopedic Rheumatology Clinic , Hokkaido, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Sagawa","sequence":"additional","affiliation":[{"name":"Sagawa Akira Rheumatology Clinic , Hokkaido, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaaki","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Yoshida Orthopaedic Surgery and Rheumatology Clinic , Iwate, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Mitsuka","sequence":"additional","affiliation":[{"name":"Mitsuka Rheumatism Clinic , Chiba, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keisuke","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Hashimoto Clinic for Rheumatic Diseases , Hyogo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomomaro","family":"Izumihara","sequence":"additional","affiliation":[{"name":"Izumihara Clinic of Rheumatism and Medicine , Kagoshima, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masakazu","family":"Kondo","sequence":"additional","affiliation":[{"name":"Kondo Clinic of Rheumatology and Orthopaedic Surgery , Fukuoka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomomasa","family":"Izumiyama","sequence":"additional","affiliation":[{"name":"Higashisendai Rheumatic Disease Clinic , Miyagi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobumasa","family":"Miyake","sequence":"additional","affiliation":[{"name":"Miyake Orthopedic Clinic , Shizuoka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ichiro","family":"Yoshii","sequence":"additional","affiliation":[{"name":"Yoshii Hospital , Kochi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motohiro","family":"Oribe","sequence":"additional","affiliation":[{"name":"Oribe Clinic of Rheumatism and Medicine , Ohita, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeki","family":"Momohara","sequence":"additional","affiliation":[{"name":"Kusanagi Orthopaedic and Rheumatologic Clinic , Shizuoka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiko","family":"Funahashi","sequence":"additional","affiliation":[{"name":"Matsubara Mayflower Hospital , Hyogo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,3,20]]},"reference":[{"key":"2024022623081177100_R1","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1007\/s40265-014-0258-9","article-title":"Etanercept: a review of its use in autoimmune inflammatory diseases","volume":"74","author":"Scott","year":"2014","journal-title":"Drugs"},{"key":"2024022623081177100_R2","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1136\/annrheumdis-2016-209166","article-title":"The changing landscape of biosimilars in rheumatology","volume":"75","author":"D\u00f6rner","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2024022623081177100_R3","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1136\/annrheumdis-2017-211591","article-title":"Long-term efficacy and safety in patients with rheumatoid arthritis continuing on SB4 or switching from reference etanercept to SB4","volume":"76","author":"Emery","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2024022623081177100_R4","article-title":"Benepali","author":"European Medicines Agency Assessment Report","year":"2018"},{"key":"2024022623081177100_R5","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1136\/annrheumdis-2017-212172","article-title":"Phase III, multicentre, double-blind, randomised, parallel-group study to evaluate the similarities between LBEC0101 and etanercept reference product in terms of efficacy and safety in patients with active rheumatoid arthritis inadequately responding to methotrexate","volume":"77","author":"Matsuno","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2024022623081177100_R6","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s40744-019-00186-3","article-title":"A comparative study to assess the efficacy, safety, and immunogenicity of YLB113 and the etanercept reference product for the treatment of patients with rheumatoid arthritis","volume":"7","author":"Yamanaka","year":"2020","journal-title":"Rheumatol Ther"},{"key":"2024022623081177100_R7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/prp2.208","article-title":"The nocebo effect of drugs","volume":"4","author":"Planes","year":"2016","journal-title":"Pharmacol Res Perspect"},{"key":"2024022623081177100_R8","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s40744-019-00190-7","article-title":"Nonmedical switching from originators to biosimilars: does the nocebo effect explain treatment failures and adverse events in rheumatology and gastroenterology?","volume":"7","author":"Fleischmann","year":"2020","journal-title":"Rheumatol Ther"},{"key":"2024022623081177100_R9","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1002\/art.40516","article-title":"Open-label, non-mandatory transitioning from originator etanercept to biosimilar SB4: six-month results from a controlled cohort study","volume":"70","author":"Tweehuysen","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2024022623081177100_R10","first-page":"1","article-title":"One-year results after transitioning from etanercept originator to biosimilar in a setting promoting shared decision-making in rheumatology","volume":"4","author":"Muskens","year":"2020","journal-title":"Rheumatol Adv Pract"},{"key":"2024022623081177100_R11","doi-asserted-by":"crossref","first-page":"69","DOI":"10.31138\/mjr.30.1.69","article-title":"Switching patients with inflammatory arthritis from etanercept (Enbrel\u00ae) to the biosimilar drug, SB4 (Benepali\u00ae): a single-centre retrospective observational study in the UK and a review of the literature","volume":"30","author":"Madenidou","year":"2019","journal-title":"Mediterr J Rheumatol"},{"key":"2024022623081177100_R12","article-title":"Denmark: Country Health Profile 2019, State of Health in the EU","author":"OECD\/European Observatory on Health Systems and Policies","year":"2019"},{"key":"2024022623081177100_R13","article-title":"Netherlands: Country Health Profile 2021, State of Health in the EU","author":"OECD\/European Observatory on Health Systems and Policies","year":"2021"},{"key":"2024022623081177100_R14","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1787\/9789264216594-17-en","volume-title":"Geographic Variations in Health Care: What Do We Know and What Can Be Done to Improve Health System Performance?","author":"Farebrother","year":"2014"},{"key":"2024022623081177100_R15","article-title":"The Health Insurance System second edition\u201d In Japan Health Policy NOW, Tokyo, Health and Global Institut","author":"Health and Global Policy Institute: \u201c3","year":"2019"},{"key":"2024022623081177100_R16","first-page":"PP35","volume-title":"The Manual of Rheumatoid Arthritis Therapy with Biologics","author":"Sagawa","year":"2010"},{"key":"2024022623081177100_R17","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1136\/annrheumdis-2018-213474","article-title":"To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry","volume":"78","author":"Glintborg","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2024022623081177100_R18","doi-asserted-by":"crossref","first-page":"257","DOI":"10.5114\/reum.2019.89516","article-title":"Observational study of inflammatory arthritis treatment by etanercept originator switched to an etanercept biosimilar","volume":"57","author":"Felis-Giemza","year":"2019","journal-title":"Reumatologia"},{"key":"2024022623081177100_R19","doi-asserted-by":"crossref","first-page":"164","DOI":"10.5772\/55641","volume-title":"In Innovative Rheumatology","author":"Matsuno","year":"2013"},{"key":"2024022623081177100_R20","doi-asserted-by":"crossref","first-page":"165","DOI":"10.5772\/55641","volume-title":"Inovative Rheumatplogy","author":"Matsuno","year":"2013"},{"key":"2024022623081177100_R21","first-page":"245","article-title":"Efficacy and safety of the switch from etabercept biosimilar to another biosimilar in patients with rheumatoid arthritis","volume":"32","author":"Matsuno","year":"2020","journal-title":"Clin Rheumatol Rel Res"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/road027\/49627624\/road027.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/34\/2\/307\/56760735\/road027.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/34\/2\/307\/56760735\/road027.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T19:52:25Z","timestamp":1729108345000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/34\/2\/307\/7082627"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,20]]},"references-count":21,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,3,20]]},"published-print":{"date-parts":[[2024,2,26]]}},"URL":"https:\/\/doi.org\/10.1093\/mr\/road027","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,3,1]]},"published":{"date-parts":[[2023,3,20]]}}}